Home > News Center
Contact Us
Shanghai BravoBio Co., Ltd.
Add:Suite 14E, Building #5, Haifu Garden, 1365 Dongfang Road, Lujiazui Financial and Trade Zone, Shanghai 200127, China
Tel: +86 21 2025 5516
Fax: +86 21 2025 5517
Email: bd@bravobio.com
News Center
Sanofi's dengue vaccine candidate shows positive PhIII data
May 8, 2014
After more than 20 years of development, Sanofi finally welcomed the positive data for its dengue vaccine candidate in one of its two phase III trials. In the first phase III trial which involved more than 10,000 children in Southeast Asia, the vaccine showed satisfying effectiveness and safety data, reducing the incidence of dengue by 56% and initial safety data matching the jab's good track record in previous studies. The second Phase III study with more than 20,000 volunteers throughout Central and South America will finish in Q3 of this year.
Currently there is no vaccine against dengue virus, the deadly tropical virus that affects up to 100 million people per year. If the second trial also goes well and the vaccine gets to market first, it may bring $1.4 billion a year in peak sales.
Pfizer will file for expedited approval with positive PhII MenB data
May 9, 2014
With positive Phase II data, Pfizer would file for expedited approval for its Men B candidate rLP2086, and compete with Novartis' Bexsero. In one study, rLP2086 showed functional immune response against MenB test strains following two or three doses. In another study, rLP2086 showed no impact on the immune response to the dTaP-IPV vaccine when the two were administered together.
GSK announced a 5-year price freeze on 3 vaccines for post-GAVI countries
May 22, 2014
GSK has been partnering with GAVI for years to offer vaccines at low cost to emerging countries. Recently, it announced a 5-year price freeze on three of its vaccines pneumococcal disease, rotavirus and HPV for countries that graduate from GAVI funding.
Top 10 best-selling vaccines of 2013
Jun. 5, 2014
The vaccine market has long been dominated by the Big 3, Sanofi, Merck and GSK. Below are top 10 best-selling vaccines of 2013, namely pfizer's prevar being No.1 with $4.048 billion sale, followed by Merck's Gardasil $2.167 billion, Sanofi's PENTAct-HIB $1.525 billion, Sanofi's Fluzone/Vaxigrip $1.396 billion, Merck's Varivax $1.377, GSK's Pediarix $1.349 billion, GSK's Hepatitis vaccine franchise $984 million, Merck's Zostavax $826 million, Merck's RotaTeq $691 million, and Merck's Pneumovax $653 million.
TechnoVax receieved a Grant from NIH to Develop a VLP based Respiratory Syncytial Virus (RSV) Vaccine
Jun. 5, 2014
A novel vaccines developer, TechnoVax, Inc., has received a SBIR (small business innovation research ) grant from NIH to support the development of an RSV vaccine utilizing its proprietary VLP technology.
Dr. Jose Galarza, CEO of TechnoVax stated, "This award recognizes not only the innovative research carried out at TechnoVax but also emphasizes the importance of developing such RSV vaccine."
GAVI nets $50M for Merck's Gardasil, GSK's Cervarix
Jun. 5, 2014
June 4, 2014, wednesday, GAVI's HPV programs obtained investment from CIFF (Children's Investment Fund Foundation) of $50M on the purchase of both Merck's ($MRK) Gardasil and GlaxoSmithKline's ($GSK) Cervarix, GAVI spokesman Rob Kelly told FierceVaccines in an email.
GAVI will use the funding to buy Gardasil for $4.50 per dose and Cervarix for $4.60 per dose to supply developing countries. And with the World Health Organization's (WHO) strategic advisory group's immunization committee recently agreeing that a two-dose course of the HPV vaccine offers sufficient protection, a full course can cost as little as $9.
Rota virus vaccines cut hospitalizations by up to 94%
Jun. 20, 2014
After the U.S. Advisory Committee on Immunization Practices (ACIP) recommended rotavirus vaccinations in 2006, Merck's RotaTeq and GSK's Rotarix together have reduced hospitalization by 94% and saved $924 million from US healthcare system. Rotavirus has practically disappeared in US since 2010.
BravoBio spoke at 2014 BioPh Summit China
Jun. 28, 2014
Ms.Xiaoshu Zhang, BD Director of Shanghai BravoBio, gave a speech on Upgrading Chinese Vaccine Industry by International Collaboration at 2014 BioPh Summit China which was held in shanghai in June 27-28. 
CDC is considering about whether to vote on recommendation of the use of Pfizer's Prevnar 13 in seniors.
Jun. 30, 2014
Prevnar is already the top-selling vaccine in the world, but ACIP recommendation is still key for expansion in the 65-plus crowd: Not only will physicians not use vaccines until they get the ACIP nod, but many payers won't cover them, either.
However, ACIP figures immunizing seniors is cost-effective in the short term, But in the long term? Possibly not, thanks to herd immunity. Because Prevnar is recommended for all children, fewer adults, too, are being sickened by the 13 types of pneumococcal bacteria that the vaccine protects against. And that effect will expand to protect more adults over the next several years, the CDC says.
Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 Next